News

The stock market jumped Thursday as Microsoft powered a big AI rebound. Apple and Amazon led earnings late.

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S

MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?

Expansion adds at least 400 jobs, taking Resilience's Ohio headcount above 1,400

Eli Lilly (NYSE:LLY) has joined Illumina's Billion Cell Atlas alliance as a foundational participant. The alliance is building what is described as the world's largest genome-wide genetic perturbation dataset. The Billion Cell Atlas is sequencing hundreds of millions of cells to map disease mechanisms and find new drug targets. Eli Lilly enters this genomic data effort with a stock that has seen very strong multi year appreciation. NYSE:LLY is trading at $1,210.02, with the share price up...

Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value and income play, the other stands out as a solid growth investment supported by rapid expansion in obesity and diabetes franchises. Pfizer Value Investment Play Pfizer (NYSE:PFE) has seen its valuation drop […]

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.

Without you picking it, a single pharmaceutical stock may have quietly become one of the largest positions inside your funds.

But is that performance sustainable?

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

The telehealth provider shared patient health information with Snap and Meta, a federal complaint says.

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lilly's pipeline is on track to pick up a handful of interesting new programs.

Will this pharma company become a new leader in the weight loss market?

Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.

The company isn't resting on its laurels.

Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.

A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits at high returns.

The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

Analysts have been lifting Eli Lilly price targets, with recent valuation work for the stock pointing to fair value of US$1,270.37 compared with the prior US$1,243.43 anchor. The shift lines up with a more constructive Wall Street stance as firms reassess the obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup, with bullish targets clustering between roughly US$1,232 and US$1,600. Ahead, you will see how this evolving narrative, both bullish and cautious, can shape how you...

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

The chief investment strategist at Concurrent Asset Management shares her top investment picks right now.